SHPMY vs ZYXI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SHPMY is a Hold and ZYXI is a Sell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SHPMY’s FA Score shows that 0 FA rating(s) are green whileZYXI’s FA Score has 1 green FA rating(s).
- SHPMY’s FA Score: 0 green, 5 red.
- ZYXI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ZYXI’s TA Score shows that 3 TA indicator(s) are bullish.
- ZYXI’s TA Score: 3 bullish, 7 bearish.
Price Growth
SHPMY (@Medical Distributors) experienced а -6.25% price change this week, while ZYXI (@Medical Distributors) price change was +0.25% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +2.82%. For the same industry, the average monthly price growth was -0.82%, and the average quarterly price growth was -12.30%.
Reported Earning Dates
ZYXI is expected to report earnings on Feb 27, 2025.
Industries' Descriptions
@Medical Distributors (+2.82% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| SHPMY | ZYXI | SHPMY / ZYXI | |
| Capitalization | 9.5B | 398M | 2,388% |
| EBITDA | 11.1B | 17.9M | 62,011% |
| Gain YTD | 14.909 | -25.528 | -58% |
| P/E Ratio | 8.39 | 46.30 | 18% |
| Revenue | 241B | 184M | 130,978% |
| Total Cash | N/A | 44.6M | - |
| Total Debt | N/A | 76.2M | - |
SHPMY | ZYXI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 86 | 99 | |
SMR RATING 1..100 | 80 | 68 | |
PRICE GROWTH RATING 1..100 | 50 | 62 | |
P/E GROWTH RATING 1..100 | 49 | 6 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SHPMY's Valuation (37) in the null industry is somewhat better than the same rating for ZYXI (95) in the Medical Specialties industry. This means that SHPMY’s stock grew somewhat faster than ZYXI’s over the last 12 months.
SHPMY's Profit vs Risk Rating (86) in the null industry is in the same range as ZYXI (99) in the Medical Specialties industry. This means that SHPMY’s stock grew similarly to ZYXI’s over the last 12 months.
ZYXI's SMR Rating (68) in the Medical Specialties industry is in the same range as SHPMY (80) in the null industry. This means that ZYXI’s stock grew similarly to SHPMY’s over the last 12 months.
SHPMY's Price Growth Rating (50) in the null industry is in the same range as ZYXI (62) in the Medical Specialties industry. This means that SHPMY’s stock grew similarly to ZYXI’s over the last 12 months.
ZYXI's P/E Growth Rating (6) in the Medical Specialties industry is somewhat better than the same rating for SHPMY (49) in the null industry. This means that ZYXI’s stock grew somewhat faster than SHPMY’s over the last 12 months.
| ZYXI | |
|---|---|
| RSI ODDS (%) | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 77% |
| Advances ODDS (%) | 2 days ago 81% |
| Declines ODDS (%) | 8 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 77% |
| Aroon ODDS (%) | 3 days ago 86% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MJRFX | 25.01 | 0.31 | +1.26% |
| BlackRock Mid-Cap Value K | |||
| SFCWX | 71.71 | 0.75 | +1.06% |
| American Funds SMALLCAP World F3 | |||
| HLIDX | 13.23 | 0.09 | +0.68% |
| Harding Loevner Intl Dev Mkts Eq Inst | |||
| AVANX | 12.77 | 0.06 | +0.47% |
| Avantis® International Small Cap Val G | |||
| HAINX | 46.64 | 0.07 | +0.15% |
| Harbor International Institutional | |||
SHPMY and
Correlation & Price change
A.I.dvisor tells us that SHPMY and NSVGF have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SHPMY and NSVGF's prices will move in lockstep.
| Ticker / NAME | Correlation To SHPMY | 1D Price Change % | ||
|---|---|---|---|---|
| SHPMY | 100% | N/A | ||
| NSVGF - SHPMY | 14% Poorly correlated | N/A | ||
| COSM - SHPMY | 12% Poorly correlated | +5.56% | ||
| SHTDF - SHPMY | 12% Poorly correlated | N/A | ||
| ZYXI - SHPMY | 7% Poorly correlated | +3.18% | ||
| SHPMF - SHPMY | 7% Poorly correlated | N/A | ||
More | ||||
ZYXI and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZYXI has been loosely correlated with OMI. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYXI jumps, then OMI could also see price increases.
| Ticker / NAME | Correlation To ZYXI | 1D Price Change % | ||
|---|---|---|---|---|
| ZYXI | 100% | +3.18% | ||
| OMI - ZYXI | 36% Loosely correlated | +2.86% | ||
| HSIC - ZYXI | 17% Poorly correlated | +0.05% | ||
| PDCO - ZYXI | 14% Poorly correlated | +1.10% | ||
| COSM - ZYXI | 13% Poorly correlated | +5.56% | ||
| GEG - ZYXI | 11% Poorly correlated | +0.56% | ||
More | ||||